Table 2.
Frequencies of Clinical Outcomes
| Clinical Outcomes – N / Total (%) | TP | TCD | P value1 |
|---|---|---|---|
| Overall success* | 13 / 28 (46) | 16 / 26 (62) | 0.2898 |
| Alive within 30 days of the procedure | 25 / 29 (86) | 26 / 28 (93) | 0.6701 |
| Effusion absent within 30 days | 18 / 29 (62) | 24 / 28 (86) | 0.0700 |
| Alive without recurrence within 30 days | 15 / 29 (52) | 23 /28 (82) | 0.0239 |
| Initial lung re-expansion ≥ 70% | 22 / 28 (79) | 19 / 26 (73) | 0.7540 |
| Chest tube ≤14 days** | 28 / 29 (97) | NA | NA |
| Effusion controlled within 60 days | 17 / 29 (59) | 22 / 28 (79) | 0.1550 |
| Talc / PleurX procedure completed | 24 / 30 (80) | 25 / 26 (96) | 0.1080 |
| Pleurodesis achieved | 25 / 29 (86) | 17 / 26 (65) | 0.1115 |
| Total drainage | |||
| Mean / Median | 1911 / 1480 | 5802 / 2484 | 0.07212 |
| Range | 300 – 6640 | 45 – 24895 | |
| Days drainage device in place | |||
| Mean/Median | 5 / 4 | 49 / 31 | < 0.00013 |
| Range | 1 – 32 | 2 – 286 | |
| Removal before death | |||
| N (%) | 29/29 (100) | 24/28 (86) | 0.0518 |
| Other survival – N (%) | |||
| Alive within 30 days | 25/29 (86) | 26/28 (93) | |
| Alive 31 – 90 days | 25/29 (86) | 19/28 (68) | 0.2616 |
| Alive beyond 90 days | 21/29 (72) | 17/28 (61) | |
| Median survival (KM estimates) | |||
| Median (days) | 147 | 147 | 0.51444 |
| 95% CI | 100 – 201 | 61 – 220 |
The definition of success is that a patient survived without effusion recurrence within 30 days, lung re-expansion ≥ 70% after desired effusion is drained, or chest tube removed before 14 days (TP only).
Applied to TP only.
p values were from Fisher’s exact 2-sided tests otherwise specified.
p value = 0.0721 was from Wilcoxon Rank Sum 2-sided test. P value = 0.0219 from linear regression analysis after adjusting for initial drainage, inpatient status at baseline, gender, whether receiving chemotherapy concurrently when enrolling to the study, and disease type (lung, breast, or other cancers). P value = 0.0969 of the same linear regression among lung and breast cancer patients only.
Wilcoxon Sum Rank two-sided test
Log-rank two-sided test